AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal.
Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis..
Price and Volume | |
---|---|
Volume | |
Ten Day Average Volume | 811.6K |
Three Month Average Volume | 12.0M |
High Low | |
Fifty-Two Week High | 22.22 USD |
Fifty-Two Week Low | 0.87 USD |
Fifty-Two Week High Date | 10 Jan 2024 |
Fifty-Two Week Low Date | 09 Aug 2024 |
Price and Volume | |
Current Price | 1.13 USD |
Beta | -100,000 |
Relative Price Change | |
Four Week Relative Price Change | -58.54% |
Thirteen Week Relative Price Change | -46.94% |
Twenty-Six Week Relative Price Change | -65.74% |
Fifty-Two Week Relative Price Change | -94.00% |
Year-to-Date Relative Price Change | -95.34% |
Price Change | |
One Day Price Change | 0.00% |
Thirteen Week Price Change | -43.22% |
Twenty-Six Week Price Change | -62.33% |
Five Day Price Change | 2.73% |
Fifty-Two Week Price Change | -92.49% |
Year-to-Date Price Change | -94.49% |
Month-to-Date Price Change | -55.69% |
Per Share Data | |
---|---|
Book Value | |
Book Value Per Share (Last Fiscal Year) | 4.19284 USD |
Book Value Per Share (Most Recent Quarter) | 3.29726 USD |
Tangible Book Value Per Share (Last Fiscal Year) | 4.19284 USD |
Tangible Book Value Per Share (Most Recent Quarter) | 3.29726 USD |
EBITD | |
EBITD Per Share (Trailing Twelve Months) | -2.47473 USD |
Revenue | |
Revenue Per Share (Last Fiscal Year) | 0 USD |
Revenue Per Share (Trailing Twelve Months) | 0 USD |
Dividend | |
Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
Dividend Per Share (Trailing Twelve Months) | 0 USD |
Dividend Per Share (5 Year) | -99999.99 USD |
Earnings Per Share | |
Excluding Extraordinary Items (Last Fiscal Year) | -2.74287 USD |
Excluding Extraordinary Items (Trailing Twelve Months) | -2.26075 USD |
Normalized (Last Fiscal Year) | -2.74287 USD |
Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.74287 USD |
Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.26075 USD |
Including Extraordinary Items (Last Fiscal Year) | -2.74287 USD |
Including Extraordinary Items (Trailing Twelve Months) | -2.26075 USD |
Cash | |
Cash Per Share (Last Fiscal Year) | 3.60759 USD |
Cash Per Share (Most Recent Quarter) | 3.50464 USD |
Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
Free Cash Flow Per Share (Trailing Twelve Months) | -2.11568 USD |
Margins | |
---|---|
Cash Flow Revenue | |
Cash Flow Revenue (5 Year) | -100,000 |
Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
Pretax Margin | |
Pretax Margin (Trailing Twelve Months) | -99,999.99% |
Pretax Margin (Last Fiscal Year) | -99,999.99% |
Pretax Margin (5 Year) | -99,999.99% |
Gross Margin | |
Gross Margin (Last Fiscal Year) | -99,999.99% |
Gross Margin (Trailing Twelve Months) | -99,999.99% |
Gross Margin (5 Year) | -99,999.99% |
Operating Margin | |
Operating Margin (Last Fiscal Year) | -99,999.99% |
Operating Margin (Trailing Twelve Months) | -99,999.99% |
Operating Margin (5 Year) | -99,999.99% |
Net Profit Margin | |
Net Profit Margin (Last Fiscal Year) | -99,999.99% |
Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
Net Profit Margin (5 Year) | -99,999.99% |
Growth | |
---|---|
Book Value | |
Book Value Per Share (5 Year) | -99,999.99% |
Tangible Book Value (5 Year) | -99,999.99% |
Free Operating Cash Flow | |
Free Operating Cash Flow (5 Year) | -99,999.99% |
Revenue | |
Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
Revenue Growth (3 Year) | -99,999.99% |
Revenue Change (Trailing Twelve Months) | -99,999.99% |
Revenue Per Share Growth | -99,999.99% |
Revenue Growth (5 Year) | -99,999.99% |
Capital Spending Debt | |
Capital Spending (5 Year) | -99,999.99% |
Total Debt (5 Year) | -99,999.99% |
Dividends | |
Dividend Growth (3 Year) | -99,999.99% |
Earnings Per Share | |
EPS Change MRQ vs 1 Year Ago | 40.29% |
EPS Change (Trailing Twelve Months) | 19.19% |
EPS Growth (3 Year) | -99,999.99% |
EPS Growth (5 Year) | -99,999.99% |
EBITDA | |
EBITDA (5 Year) | -99,999.99% |
EBITDA (5 Year Interim) | -99,999.99% |
Net Profit Margin | |
Net Profit Margin Growth (5 Year) | -99,999.99% |
Valuation | |
---|---|
Total Price to Book | |
Price to Tangible Book (Last Fiscal Year) | 0 |
Price to Tangible Book (Most Recent Quarter) | 0 |
Price to Free Cash Flow | |
Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
Net Debt | |
Net Debt (Most Recent Quarter) | -104,540,000 |
Net Debt (Last Fiscal Year) | -107,295,000 |
Price to Sales | |
Price to Sales (Last Fiscal Year) | -100,000 |
Price to Sales (Trailing Twelve Months) | -100,000 |
Price to Earnings | |
PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
PE Normalized (Last Fiscal Year) | -100,000 |
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
Dividends | |
Dividend Yield (5 Year) | -99,999.99% |
Dividend Yield | -99,999.99% |
Current Dividend Yield | 0.00% |
Price to Book | |
Price to Book (Last Fiscal Year) | 0 |
Price to Book (Most Recent Quarter) | 0 |
Financial Strength | |
---|---|
Debt to Equity | |
Long Term Debt to Equity (Last Fiscal Year) | 0 |
Long Term Debt to Equity (Most Recent Quarter) | 0 |
Payout Ratio | |
Payout Ratio (Last Fiscal Year) | -99,999.99% |
Payout Ratio (Trailing Twelve Months) | -99,999.99% |
Quick Ratio | |
Quick Ratio (Last Fiscal Year) | -100,000 |
Quick Ratio (Most Recent Quarter) | -100,000 |
Enterprise Value | |
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
Current Ratio | |
Current Ratio (Last Fiscal Year) | 8 |
Current Ratio (Most Recent Quarter) | 11 |
Free Cash Flow | |
Free Cash Flow (Last Fiscal Year) | -53,288,000 |
Free Cash Flow (Trailing Twelve Months) | -60,845,000 |
Net Interest Coverage | |
Net Interest Coverage (Last Fiscal Year) | -100,000 |
Net Interest Coverage (Trailing Twelve Months) | -100,000 |
Total Debt to Equity | |
Total Debt to Equity (Last Fiscal Year) | 0 |
Total Debt to Equity (Most Recent Quarter) | 0 |
Management Effectiveness | |
---|---|
Return on Assets | |
Return on Assets (Last Fiscal Year) | -53.65% |
Return on Assets (Trailing Twelve Months) | -62.35% |
Return on Assets (5 Year) | -99,999.99% |
Return on Equity | |
Return on Equity (Last Fiscal Year) | -58.83% |
Return on Equity (Trailing Twelve Months) | -69.48% |
Return on Equity (5 Year) | -99,999.99% |
Return on Investment | |
Return on Investment (Last Fiscal Year) | -58.83% |
Return on Investment (Trailing Twelve Months) | -69.48% |
Return on Investment (5 Year) | -99,999.99% |